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many	 of	 them	have	been	 recognized	 as	 probiotics.	
Probiotics	 have	 been	 defined	 as	 “live	 microorgan-
isms	which	when	administered	in	adequate	amounts	
confer	 a	 health	 benefit	 on	 the	 host”	 (FAO/WHO,	
2001;	Hoesl	 and	Altwein,	 2005).	Many	positive	
actions	of	probiotics	in	human	gastrointestinal	tract	
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have	 been	 well	 known	 and	 investigated	 (Reid	 et	
al.,	 2003;	 Saarela	 et	 al.,	 2000;	 Samaržija	 et	 al.,	







Anuradha	 and	 Rajeshwari,	 2005).	 Between	
many	 of	 scientifically	 confirmed	 health-beneficial	




(lactobacilli)	 as	 protection	 agents	 against	UTI	 still	
has	 been	 strongly	 controversial,	 in	many	 countries	
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their	 pharmaceutical	 application	 for	 the	 treatment	
of	 urogenital	 infections	 (UGI)	 in	 women	 already	
exists	(Kaur	et	al.,	2002;	Nomoto,	2005).	







al.,	 2003b;	 Forsum	 et	 al.,	 2005;	Anukam	 et	 al.,	
2006)	 ingestion	of	probiotics	with	 fermented	 food	
could	 potentially	 influence	 prevention	 of	 UTI	 or	




ing,	 this	does	not	yet	 reflect	 the	commercial	 front	
(Reid,	2003a).		Unfortunately,	many	so-called	pro-
biotic	products	on	the	world	market	have	not	been	
properly	 identified,	 documented,	manufactured	 or	
proven	 clinically	 (Reid	 and	 Bruce,	 2006;	 Reid,	
2010).	 In	such	situation,	consumers	and	caregivers	
are	 not	 sure	 that	 they	 are	 using	 reliable	 products,	
and	 have	 been	 confided	 only	 to	 pharmaceutical	
preparations.	






Urogenital infections (UGI): pathology and status 
in the health care system






(UGI)	 include	urinary	 tract	 infections	 (UTI),	bac-
terial	 vaginosis	 (BV)	 and	 yeast	 vaginitis	 (Reid	 et	
al.,	 2001a).	 Scientific	 data	 indicates	 that	 the	 vast	
majority	 of	UTI	 in	 non-hospitalized	 community	 is	
caused	by	Escherichia coli	(70	%),	followed	by	other	
uropathogens	 such	 as	 Enterococcus faecalis,	 Kleb-
siella pneumoniae,	 Pseudomonas aeruginosa,	 group	
B	 streptococci,	 Providencia stuartii,	 and	 Staphy-
lococcus epidermis	 (Reid	 and	 Seidenfeld,	 1997;	
Reid	 and	Bruce,	2001).	BV	 is	 an	 infection	of	 fe-
male	 genital	 tract	 characterized	 by	 an	 overgrowth	
of	 aerobic,	 anaerobic	 and	 micro-aerophilic	 species	
such	as	Gardnerella vaginalis,	Mycoplasma hominis,	
Ureaplasma urealyticum,	 Peptostreptococcus	 spp.,	
Prevotella	 spp.	 and	Mobilnicus	 spp.	 (Rosenstein	




a	 negative	 impact	 on	 the	 quality	 of	 patient’s	 life,	
as	well	as	on	the	total	health	condition	of	patients	
(Ellis	 and	Verma,	 2000).	Effectiveness	 of	 antibi-
otic	therapy	of	BV	and	UTI	has	been	closely	related	
to	 uropathogen	 resistance	 (Marelli	 et	 al.,	 2004).	
A	great	problem	 in	 treatment	of	patients	with	BV	
and	 UTI	 is	 the	 increase	 of	 pathogen	 drug	 resist-
ance	 in	 many	 countries	 (Reid	 and	 Seidenfeld,	




(2006)	 reported	 that	 four	 family	medicine	 offices	
found	an	incidence	of	urinary	infections	greater	than	





cal	 results	 from	 other	 European	 countries	 (Felm-





Probiotic lactobacilli and urogenital infectios: 
scientific base and mode of action
	 Lactobacilli	 are	 gram-positive	 rods,	 facultative	
or	 strict	anaerobes	which	prefer	an	acidic	environ-
ment	 and	help	 create	 one	 by	 producing	 lactic	 and	
other	acids	(Marelli	et	al.,	2004;	Saarela,	2000).	




and	 Bruce,	 2006;	 Anuradha	 and	 Rajeshwari,	
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2005).	The	use	of	probitics	for	the	health	of	female	













vaginal	 flora	 consists	 of	 lactobacilli,	 which	 possess	
antimicrobial	properties	that	regulate	other	urogeni-
tal	 microbiota	 (Forsum	 et	 al.,	 2005).	 Urogenital	











	 There	 is	 another	 basic	 question:	 what	 prop-
erties	 do	 these	 lactobacilli	 strains	 have	 that	 make	
them	effective	probiotic	agents	 in	urogenital	 tract?	










1.	ability	 of	 adhesion	 to	 vaginal	 epithelial	 cells	
(McLean	 and	Rosenstein,	 2000;	 Ehström	 et	
al.,	2010),
2.	production	of	biosurfactants	and	collagen-binding	



















Lactobacillus casei	 strain	 Shirota	 (Asahara	 et	 al.,	
2001)	and	Lactobacillus acidophilus	NCFM	(Reid,	
2000),	but	not	in	full.	All	of	these	three	strains	pos-
sess	 antimicrobial	 capacity	 against	 uropathogens,	
but	 also	have	 some	of	defective	properties	 in	uro-
genital	 environment.	 For	 example,	 L. acidophilus	




of	 the	 known	 key	 factors	 and	 be	 able	 to	 compete	
in	 the	urogenital	environment.	Bacterial	 adherence	
is	 considered	 to	 be	 an	 important	 first	 step	 in	 the	
colonization	of	urogenital	tissue	(McLean	and	Ro-
senstein,	2000).	Lactobacilli	can	use	many	mech-















wall	 adhesion.	Furthermore,	 some	 strains	 can	bind	
better	to	intestinal	cells	and	inhibit	pathogen	adhe-
sion	(Reid	et	al.,	1993;	Hudault	et	al.,	1994),	but	
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they	may	not	be	 able	 to	effectively	 inhibit	 growth	
of	 uropathogens	 (Reid	 et	 al.,	 1987;	Osset	 et	 al.,	
2001).	Studies	on	vaginal	colonization	by	lactobacilli	
in	humans	have	focused	largely	on	oral	or	intravagi-







	 In	 addition,	 lactobacilli	 may	 offer	 protection	
against	urogenital	 infections	 through	production	of	








produced	 by	 certain	 lactobacilli	 hold	 promise	 for	
application	 to	 many	 human	 sites	 where	 pathogen	
attach,	colonize	and	confer	disease	(Marelli	et	al.,	
2004).	 Biosurfactants	 produced	 by	 lactobacilli	 are	
most	 frequently	 glycolipids	 but	 also	 lipopeptides,	
protein-like	 substances,	 phospholipids,	 substituted	







	 Another	 protective	 characteristic	 of	 urogeni-
tal	 lactobacilli	 is	ability	of	co-aggregation	with	uro-




Gardnerella vaginalis	 among	 10	 strains	 of	 lactoba-
cilli	that	were	being	used	in	probiotic	vaginal	tablets.	
Mechanism	 of	 lactobacilli-pathogen	 co-aggregation	
and	the	contribution	of	these	individual	antibacterial	
properties	to	clinical	efficacy	are	recently	unclear.	
	 Same	 like	 in	 the	 prevention	 of	 intestinal	 dis-
orders,	 for	use	 as	probiotics	 in	 the	prevention	 and	
treatment	of	urogenital	infections,	lactobacilli	must	
exhibit	 adequate	 antibacterial	 activity.	 The	 most	




important	 factor	 in	 controlling	 the	 composition	 of	




of	 antimicrobial	 activity	also	contained	 the	highest	
levels	 of	 lactic	 acid.	Except	 lactic	 acid,	 lactobacilli	
produce	 additional	 antibacterial	 substances,	 such	
as	 bacteriocins	 and	 hydrogen-peroxide	 (Aroutch-
eva	 et	 al.,	 2001).	 Different	 strains	 of	 lactobacilli	
produce	varying	amounts	of	these	substances.	Most	
lactobacilli	are	able	to	produce	hydrogen	peroxide.	
Hydrogen	 peroxide	 has	 a	 toxic	 potential	 towards	
pathogen	bacteria	but	also	 to	 the	producing	bacte-
ria	 themselves.	 Its	 antimicrobial	 effect	 is	based	on	
its	oxidative	properties	which	results	in	irreversible	





hydrogen	 peroxide	 -	 producing	 lactobacilli	 against	
bacterial	 vaginosis	 has	 been	 observed	 by	 several	
studies	 (Eschenbach	 et	 al.,	 1989;	Hawes	 et	 al.,	






stein	 et	 al.,	 1997).	 In	 general,	 according	 to	many	
biological	statements,	hydrogen	peroxide	produced	
by	urogenital	 lactobacilli	 could	have	 important	 an-
tagonistic	effect	against	undesirable	microorganisms,	







were	 isolated	 from	 food	 and	 raw	materials,	 but	 it	
can	not	 be	 shown	yet	 that	 vaginal	 lactobacilli	 pro-
duce	bacteriocins	(Reid,	2001;	Merk	et	al.,	2005).	
However,	 bacteriocin-like	 substances	 produced	 by	
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different	 strains	 of	 urogenital	 lactobacilli	 could	 be	
described	 and	 isolated	 (McGroarty	 and	 Reid,	






Gram-negative	 bacteria	 (McGroarty,	 1993).	 An-
tagonistic	 action	 of	 mentioned	 substances	 against	
Clostridium sporogenes,	 Clostridium tyrobutyri-
cum,	 Listeria inocua,	 Propionibacterium species,	





Oral administration of probiotic lactobacilli for 
prevention and treatment of urogenital infections: 
clinical evidence
	 It	 is	 well	 known	 and	 scientifically	 confirmed	
that	some	selected	probiotic	strains	applied	direct-























































sexually	 transmitted	 diseases	 infestation	 (Reid	 et	
al.,	2001a).	From	all	of	these	reasons,	it	is	very	inter-
esting	for	food	industry	to	produce	certain	products	
with	 potential	 protective	 role	 for	 urogenital	 tract.	
Is	it	real	and	possible?	A	number	of	positive	scien-
tific	 evidences	 about	 beneficial	 effects	 of	 selected	














try	 to	 produce	 some	 fermented	 or	 non	 fermented	
dairy	 food	 containing	 probiotic	 lactobacilli,	 which	
have	potential	protective	properties	for	the	urogeni-
tal	tract	of	consumers.	A	number	of	questions	and	
dilemmas	 could	 be	 raised:	 How	 these	 urogenital-
effective	 strains	of	 lactobacilli	 grow	 in	milk?	What	
are	the	inhibiting	factors	for	their	growth	in	milk?	In	
what	form	these	urogenital-protective	strains	could	






the	 selected	 probiotic	 lactobacilli	 strains	 from	 fer-
mented	food	equally	effective	like	these	from	phar-
maceutical	preparations?
	 Antagonistic	 effect	 of	 commercially	 available	
probiotic	Lactobacillus	strains	against	uropathogens	
have	 been	proved	 in	 a	 number	 of	 in vitro	 studies,	
same	 like	 their	 ability	 to	 colonize	 epithelial	 cells	
of	vagina	(Chan	et.	al.,	1985;	Sieber	and	Deitz,	





bacilli	 strains	 raise	 questions	 about	 the	 design	 of	
these	studies	and	emphasize	the	need	for	additional	




ascent	 of	 the	uropahnogens	 to	 the	bladder.	Oppo-
site,	 group	 of	 Finish	 researches	 in	 a	 study	 of	 185	
women	with	5-years	UTI-free	history	found	that	the	
subjects	consuming	the	Lactobacillus GG drinks,	at	
least	 three	 times	per	week,	had	 fewer	 episodes	of	
UTI	compared	 to	 those	women	not	 receiving	pro-
biotics	(Kontiokari	et	al.,	2001).	Reid	(2000)	re-
ported	that	the	application	of	L. acidophilus NCFM	
strain	 to	 humans	 might	 be	 effective	 in	 urogenital	
tract	if	applied	directly	to	the	vagina,	but	not	by	oral	
ingestion,	whereas	the	results	of	Neri	et	al.	(1993)	
clearly	 show	 beneficial	 effect	 of	 consumption	 of	
yoghurt	with	incorporated	L. acidophilus	cells	on	BV	
status	of	84	women	in	first	trimester	of	pregnancy.	
	 A	 number	 of	 similar	 opportunistic	 episodes	
have	 been	 noted	 in	 scientific	 literature.	 However,	
some	positive	and	optimistic	scientific	data	have	to	
be	referred.	The	results	of	 the	randomized	clinical	
observations	 have	 emphasized	 beneficial	 effects	 of	
therapy	with	probiotic	milk	(food)	to	health	status	
of	women	with	BV	or	 vulvovaginal	 candiasis	 (VC)	
(Neri	et	al.,	1993;	Reid	et	al.,	2001a;	Demirezen,	
2002;	Jeavons,	2003;	Reid	et	al.,	2001b;	Reid	et	
al.,	 2003b;	 Anukam	 et	 al.,	 2006;	 Falagas	 et	 al.,	
2006).	 Clinically	 controlled	 ingestion	 of	 probiotic	
lactobacilli	from	fermented	food	influenced	greatly	
on	 a	 reduction	 of	 vaginal	 infections	 and	 improves	
the	overall	urogenital	health	of	tested	women	sub-
jects.	Moreover,	 clinically	 controlled	 therapy	 with	
probiotic	 dairy	 food,	 used	 separately	 or	 combined	
with	 appropriate	 antibiotcs;	 influenced	 frequently	
to	 total	 absence	of	BV	and	VC	after	proper	 treat-
ment	period	(Anukam	et	al.,	2006;	Falagas	et	al.,	
2006).	Lesser	than	 in	case	of	BV	and	VC,	positive	
role	of	probiotic	 lactobacilli	 oral	 ingestion	was	 sci-
entifically	confirmed	for	the	prevention	of	UTI.	In	
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a	 randomized,	open-label	 study,	Kontiokari	et	 al.	
(2001)	observed	that	consummation	of	dairy	probi-
otic	drink	and	cranberry-lingoberry	juice	influencing	





appear.	 There	 is	 need	 to	 select	 probitic	 strains	 on	
the	basis	of	functional	attributes	in	urogenital	tract,	
and	 based	 on	 this,	 a	 particular	 culture	 (or	mix	 of	








	 Finally,	 the	 dose	 required	 for	 probiotic	 lacto-
bacilli	to	impact	vaginal,	or	urinary	tract	flora	must	
be	clearly	defined.	Findings	of	Reid	et	al.	(2001b)	
indicate	 that	 a	 daily	 oral	 dose	 of	 108	viable	 probi-
otic	lactobacilli	(GR-1	and	RC-14),	can	restore	and	
maintain	 the	 urogenital	 health	 of	 a	women.	How-




	 Different	 strains	 of	 lactobacilli	 have	 differ-
ent	 potential	 to	 be	 effective	 against	 pathogens	 in	
urogenital	 tract.	 Their	 efficacy	 has	 been	 based	 on	
their	characteristics,	but	also	on	 their	bahaviour	 in	
urogenital	tract.	Although	many	of	their	character-
istics	 required	 to	 confer	 protection	 of	 urogenital	
tract	have	been	identified in vitro,	evidence	of	their	







opportunity,	 because	 they	 provide	 a	major	 step	 in	




their	 fermentative	products,	 needs	 to	 be	 addition-
ally	investigated	and	processing	parameters	must	be	
determined.
Prevencija urogenitalnih infekcija oralnim 
unosom probiotičkih laktobacila
Sažetak





djelovati	 putem	 sljedećih	mehanizama:	 adhezija	 na	
stanice	 urogenitalnog	 trakta,	 natjecanje	 s	 patogeni-
ma	za	adhezivna	mjesta,	produkcija	biosurfaktanata,	








binacija	 bakterija	 Lactobacillus rhamnosus	 GR-1	 i	
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